# Efficacy and Safety Study of Meloxicam Nanocrystal Injection for the Treatment of Moderate to Severe Pain

> **NCT06379165** · PHASE3 · COMPLETED · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 192 (actual)

## Conditions studied

- Pain

## Interventions

- **DRUG:** Meloxicam Nanocrystal Injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06379165
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-17
- **Primary completion:** 2023-07-11
- **Final completion:** 2023-07-13
- **Target enrollment:** 192 (ACTUAL)
- **Last updated:** 2024-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06379165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06379165, "Efficacy and Safety Study of Meloxicam Nanocrystal Injection for the Treatment of Moderate to Severe Pain". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06379165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*